Bury R W, Becker G J, Kincaid-Smith P S, Moulds R F, Whitworth J A
Clin Pharmacol Ther. 1987 Apr;41(4):434-8. doi: 10.1038/clpt.1987.53.
The elimination of enoxacin was investigated in 15 subjects, 10 of whom were hospital outpatients with renal disease and varying degrees of renal impairment. Each was given enoxacin orally (200 mg b.i.d.) for 7 days. Blood specimens collected over 24 hours after the final dose of enoxacin and urine collected during the 12-hour dose interval after the final dose were assayed for enoxacin by HPLC. The elimination half-life of enoxacin increased with worsening renal function. In general, patients with diminished renal function had lower plasma enoxacin clearance values than had normal subjects, and a statistically significant correlation between apparent oral clearance and creatinine clearance was observed. Excretion of enoxacin by the kidney accounted for 26% to 72% of the apparent plasma clearance in normal subjects. This was markedly reduced in patients with severe renal failure.
对15名受试者的依诺沙星消除情况进行了研究,其中10名是患有肾脏疾病且肾功能有不同程度损害的医院门诊患者。每位受试者口服依诺沙星(200毫克,每日两次),持续7天。在最后一剂依诺沙星后的24小时内采集血样,并在最后一剂后的12小时给药间隔内收集尿液,通过高效液相色谱法测定其中的依诺沙星。依诺沙星的消除半衰期随着肾功能恶化而延长。一般来说,肾功能减退的患者血浆依诺沙星清除率值低于正常受试者,并且观察到表观口服清除率与肌酐清除率之间存在统计学上的显著相关性。在正常受试者中,肾脏对依诺沙星的排泄占表观血浆清除率的26%至72%。在严重肾衰竭患者中,这一比例明显降低。